Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 06/23/25
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference TranscriptSeeking Alpha • 06/23/25
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsPRNewsWire • 06/22/25
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of MedicinePRNewsWire • 06/21/25
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen saysReuters • 06/20/25
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demandReuters • 06/20/25
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERVBusiness Wire • 06/19/25
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss StudyBenzinga • 06/18/25
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.The Motley Fool • 06/18/25
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug ZepboundFast Company • 06/17/25
This one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli LillyMarket Watch • 06/17/25
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies sayReuters • 06/17/25
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPRNewsWire • 06/17/25